Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Assessing the Safety & Efficacy of an Affordable Fracture External Fixation System (AEFIX)

tiistai 10. marraskuuta 2026 päivittänyt: Beth Israel Deaconess Medical Center

AEFIX Trial: A Multicenter, Open-Label, Randomized Pivotal (Phase III) Clinical Trial Assessing the Safety and Efficacy of a Novel, Affordable External Fixation System for the Management of Femur and Tibia Fractures in Adults

The goal of this clinical trial is to learn whether AEFIX, a new low-cost external fixation system, works as well as the external fixators currently used in Rwandan public hospitals to hold broken thigh (femur) and shin (tibia) bones in position in adults. External fixation uses metal pins placed into the bone and connected by clamps and rods outside the body. It is commonly used for severe fractures, including open fractures, that cannot safely be treated with internal plates or rods right away.

The main questions it aims to answer are:

  • Does AEFIX keep the broken bone in position as well as standard external fixators, as measured on X-rays taken after surgery and again before the fixator is removed?
  • How do complications, quality of life, and fracture healing compare between the two groups?

Researchers will compare AEFIX to the external fixation systems already used as standard care at each participating hospital to see whether AEFIX is no worse than these systems at keeping the bone in place.

Participants will:

  • Be randomly assigned, like a coin toss, to receive either AEFIX or the standard external fixator during their planned fracture surgery
  • Have X-rays after surgery and before the external fixator is removed
  • Return for follow-up visits about 6 weeks, 3 months, 6 months, and 12 months after surgery, where the study team will check pin sites, healing, pain, and ability to bear weight, and ask questions about quality of life
  • Receive reimbursement for transport costs to attend follow-up visits

About 150 adults will take part at up to five hospitals in Rwanda.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Background Musculoskeletal trauma is common and rising in Rwanda, driven largely by road traffic injuries, and open fractures of the tibia are among the most frequent and serious injuries treated at referral hospitals. External fixation is the standard of care for temporary, and sometimes definitive, stabilization of fractures that cannot safely undergo internal fixation because of infection risk, soft tissue injury, or patient instability. Industry-standard external fixator clamps cost approximately 500 USD each, which limits their availability in public hospitals in low- and middle-income countries, where many fixators in use are donated or reprocessed. AEFIX is an affordable modular external fixation system (approximately 15 USD per clamp) made from medical-grade hard coat anodized aluminum and stainless steel. Laboratory mechanical testing has shown performance comparable to industry-standard clamps. This trial evaluates whether AEFIX is non-inferior to locally available external fixation systems in routine clinical practice in Rwanda.

Design This is a multicenter, pragmatic, open-label, parallel-arm randomized controlled trial with a non-inferiority design. Eligible participants are randomized 1:1 in the operating theatre, after final confirmation of eligibility, using a centralized web-based randomization system. Participants in the comparator arm receive the external fixation system routinely used at the participating site. The brand and model of each comparator construct, and whether components were previously used and reprocessed, are recorded for every participant, and each construct is photographed at application. Comparator systems at participating sites are predominantly Stryker Hoffmann 3. All participating surgeons complete a dedicated instructional course on the AEFIX technique before using the device.

Staged site activation Enrollment begins at the University Teaching Hospital of Kigali (CHUK) and the University Teaching Hospital of Butare (CHUB). Approximately the first 70 participants constitute an initial feasibility stage assessing recruitment rate (target of more than 3 participants per site per month), retention, and adherence to randomized allocation. Three district hospitals (Kabgayi, Kibagabaga, and Kibogora) will be activated following review of feasibility data by the independent Data and Safety Monitoring Committee (DSMC), or earlier if recruitment at CHUK and CHUB remains below target after three months of enrollment.

Sample size Assuming approximately 95% maintenance of fracture reduction in both arms, 74 participants (37 per arm) provide 90% power to demonstrate non-inferiority with a one-sided alpha of 0.05 and a non-inferiority margin of 15%. Allowing for up to 50% loss to follow-up, the trial will enroll 150 participants (75 per arm).

Statistical analysis The primary analysis follows the intention-to-treat principle and includes all comparator systems, reflecting routine practice. Per-protocol and as-treated analyses will assess robustness given the possibility of intraoperative device crossover. A pre-specified secondary analysis repeats the non-inferiority comparison among participants treated with AEFIX or Stryker Hoffmann 3, the predominant comparator, to provide a direct device-to-device comparison. Missing data will be handled by multiple imputation under a missing-at-random assumption, with sensitivity analyses. The trial biostatistician remains blinded to treatment allocation until database lock; the allocation key is held by an independent data manager with no role in outcome assessment or analysis.

Safety oversight An independent five-member DSMC with expertise in surgery, clinical research, research ethics, and biostatistics, based in Rwanda and the United States, meets quarterly and as needed. DSMC members have no financial relationship with the manufacturer of the investigational device or of the comparator devices. Causality of all adverse events is determined by the DSMC, independently of the study investigators and the device developer. Serious adverse device effects are reported to the Rwanda Food and Drugs Authority and the Rwanda National Research Ethics Committee in accordance with national requirements and ISO 14155:2020.

Conflict of interest The AEFIX device is developed and donated by SONA Global, a nonprofit organization founded by a study co-investigator, who receives no income, compensation, or equity from the organization.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

150

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Jean de la Croix Allen Ingabire, MD, PhD
  • Puhelinnumero: +250 788 549 975
  • Sähköposti: ijea2000@gmail.com

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

      • Huye, Ruanda
        • University Teaching Hospital of Butare (CHUB)
        • Ottaa yhteyttä:
          • Jean de la Croix Allen Ingabire, MD, PhD
          • Puhelinnumero: +250 788 549 975
          • Sähköposti: ijea2000@gmail.com
      • Kigali, Ruanda
        • University Teaching Hospital of Kigali (CHUK)
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
        • Päätutkija:
          • Marie Grace Kansayisa, MD
      • Kigali, Ruanda
        • Kibagabaga District Hospital
        • Ottaa yhteyttä:
          • Jean de la Croix Allen Ingabire, MD, PhD
          • Puhelinnumero: +250 788 549 975
          • Sähköposti: ijea2000@gmail.com
      • Muhanga, Ruanda
        • Kabgayi District Hospital
        • Ottaa yhteyttä:
          • Jean de la Croix Allen Ingabire, MD, PhD
          • Puhelinnumero: +250 788 549 975
          • Sähköposti: ijea2000@gmail.com
      • Nyamasheke, Ruanda
        • Kibogora District Hospital
        • Ottaa yhteyttä:
          • Jean de la Croix Allen Ingabire, MD, PhD
          • Puhelinnumero: +250 788 549 975
          • Sähköposti: ijea2000@gmail.com

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Age 18 years or older.
  • Closed or open fracture of the femur and/or tibia, including fractures of the proximal femur, femoral diaphysis, extra-articular and intra-articular fractures of the distal femur and proximal tibia, tibial diaphysis, and extra-articular and intra-articular fractures of the distal tibia, including pilon and ankle fractures.
  • Fracture not amenable to internal fixation due to risk of infection, inadequate soft tissue coverage, severe soft tissue trauma, or hemodynamic instability, and therefore indicated for external fixation by the treating surgeon.
  • All planned surgeries to be performed by a participating surgeon or delegate at a study site (no pre-operative plan for transfer to another facility or surgeon after external fixation).
  • Informed consent obtained from the patient or, if the patient is unable to consent because of their injury, from a healthcare proxy or legally authorized representative.

Exclusion Criteria:

  • Established fracture malunion or nonunion, including any patient undergoing correction of deformity or management of a malunion, nonunion, or delayed union.
  • Established chronic osteomyelitis or pathologic fracture.
  • Limb deformity correction or bone transport.
  • Periprosthetic fracture.
  • Incarceration.
  • Current enrollment in another study that does not permit co-enrollment.
  • Unable to provide informed consent due to language barriers.
  • Prior enrollment in this study.
  • Fracture pattern or anatomical condition precluding safe placement of Schanz pins in established anatomical safe zones, as determined intraoperatively by the participating surgeon.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: AEFIX External Fixation

Participants receive fracture external fixation using the AEFIX system, an affordable modular external fixator consisting of AEFIX clamps (hard coat anodized aluminum), 11 mm aluminum connecting rods, and 5 mm Schanz pins. Components are steam sterilized on site before use. Pins are placed bicortically in anatomical safe zones and connected by clamps and rods in a unilateral double-rod or modular frame construct. The fixator remains in place until removal by the treating surgeon for staged conversion to internal fixation or after definitive treatment.

Investigational modular external fixation system (clamps, connecting rods, and Schanz pins) designed for affordability in resource-limited settings. Clamps are made of medical-grade hard coat anodized aluminum and stainless steel, supplied non-sterile, and steam sterilized before single use. Manufactured by an ISO 13485-certified contract manufacturer for SONA Global.

Active Comparator: Standard of Care External Fixation

Participants receive fracture external fixation using the locally available external fixation system routinely used as standard of care at the participating hospital, most commonly donated or reprocessed modular systems from established manufacturers (predominantly Stryker Hoffmann 3; also DePuy Synthes and others). The brand and model of each comparator construct, and whether components were previously used and reprocessed, are recorded for every participant, and each construct is photographed at application. The fixator remains in place until removal by the treating surgeon for staged conversion to internal fixation or after definitive treatment.

Commercially available modular external fixation systems already in routine clinical use at participating hospitals, not supplied by the sponsor. Device brand, model, and reprocessing history are documented for each participant.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Loss of Fracture Reduction
Aikaikkuna: From initial postoperative radiograph (within 24 hours of external fixator application) to final radiograph (within 48 hours before external fixator removal), up to 12 months

Proportion of participants with loss of fracture reduction, defined as any of the following between the initial postoperative radiograph and the final radiograph before external fixator removal: angular deformity change greater than 5 degrees in the coronal or sagittal plane; translational displacement greater than 10 millimeters in any plane; or increase in fracture gap greater than 10 millimeters, measured using calibrated digital radiographic tools. Participants with more than one fracture treated with external fixation are counted as having loss of reduction if it occurs in any treated fracture. Non-inferiority of AEFIX relative to locally available external fixation systems is assessed using a pre-specified margin of 15% and a one-sided alpha of 0.05.

From initial postoperative radiograph (within 24 hours of external fixator application) to final radiograph (within 48 hours before external fixator removal), up to 12 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Participants With Clinical Complications, by Type
Aikaikkuna: 6 weeks, 3 months, 6 months, and 12 months after initial surgery

Clinical complications include pin tract infection, superficial infection, deep infection, iatrogenic neurovascular injury, malunion, nonunion, amputation, and death, reported as the number of participants experiencing each complication per treatment arm.

6 weeks, 3 months, 6 months, and 12 months after initial surgery
Health-Related Quality of Life (EQ-5D-5L Index Score)
Aikaikkuna: 6 weeks, 3 months, 6 months, and 12 months after initial surgery

The EQ-5D-5L measures five dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels, and is summarized as an index score where 1 represents full health and 0 represents a state equivalent to death; values below 0 are possible. Higher scores indicate better health-related quality of life. A difference of 0.074 is considered the minimum clinically important difference.

6 weeks, 3 months, 6 months, and 12 months after initial surgery
Functional Fracture Healing (Functional IndeX for Trauma [FIX-IT] Score)
Aikaikkuna: 6 weeks, 3 months, 6 months, and 12 months after initial surgery

The FIX-IT score assesses ability to bear weight (0 to 6 points) and pain at the fracture site (0 to 6 points), for a total score ranging from 0 to 12. Higher scores indicate better clinical fracture healing and function. A change of 2 or more points is considered clinically meaningful.

6 weeks, 3 months, 6 months, and 12 months after initial surgery

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Jean de la Croix Allen Ingabire, MD, PhD, University of Rwanda

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Tiistai 1. joulukuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Torstai 1. maaliskuuta 2029

Opintojen valmistuminen (Arvioitu)

Perjantai 1. helmikuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 10. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 17. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 17. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

De-identified individual participant data underlying the results reported in publications, including primary and secondary outcome data and baseline characteristics, will be made available to qualified researchers upon reasonable request. Data are owned by the University of Rwanda; sharing is subject to approval by the University of Rwanda and the Rwanda National Research Ethics Committee, compliance with Rwandan data protection law, and execution of a data use agreement.

IPD-jaon aikakehys

Beginning 6 months after publication of the primary results and ending 5 years after publication.

IPD-jaon käyttöoikeuskriteerit

Requests from qualified researchers with a methodologically sound proposal will be reviewed by the study investigators and the University of Rwanda. Approved requesters must sign a data use agreement prohibiting re-identification and limiting use to the approved proposal. Requests should be directed to the Principal Investigator.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa